Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Add as a preferred source on Google
FREDERICK, MD, May 02, 2018 -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that two meetings have been scheduled with the US Food and Drug Administration (FDA) to seek expanded over-the-counter (OTC) clearances for their drug-free, wearable medical devices.
The first meeting will take place on May 9th, 2018 to seek expanded indications for OTC treatment of all musculoskeletal pain for its ActiPatch® medical device. BioElectronics currently has OTC clearances for adjunctive treatment of two types of musculoskeletal pain: 1) Knee osteoarthritis 2) Plantar Fasciitis. Per the FDA’s requirement to obtain clearance for all musculoskeletal pain, the company submitted the results of a low back pain clinical study, via a Pre-Submission in April 2018. Full details about the study can be found at the NIH’s clinical trials listing page.
The second meeting will take place on May 29th, 2018 to seek expanded indications for OTC treatment of pain and edema following surgical procedures for its RecoveryRx® medical device. BioElectronics currently has a prescription-only clearance for the treatment of edema following blepharoplasty (eye-lid corrective surgery). The company has submitted clinical evidence to the FDA from a breast augmentation study and C-section study, via a Pre-Submission in April 2018.
Sree Koneru, Ph.D., VP of Product Development at BioElectronics, expressed confidence in the upcoming meetings and in the strength of the clinical evidence. “The clinical studies that were submitted have been conducted in an independent and rigorous manner, so we are looking forward to working with the FDA and seek their guidance to obtain expanded market clearances in a timely manner,” Mr. Whelan said.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. For more information, please visit www.bielcorp.com.
Paul Knopick 9402623584 [email protected]
